153 related articles for article (PubMed ID: 23648398)
1. The incidence of acute urinary retention secondary to BPH is increasing among California men.
Groves HK; Chang D; Palazzi K; Cohen S; Parsons JK
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):260-5. PubMed ID: 23648398
[TBL] [Abstract][Full Text] [Related]
2. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.
Desgrandchamps F; De La Taille A; Doublet JD;
BJU Int; 2006 Apr; 97(4):727-33. PubMed ID: 16536763
[TBL] [Abstract][Full Text] [Related]
3. Acute urinary retention increases the risk of complications after transurethral resection of the prostate: a population-based study.
Chen JS; Chang CH; Yang WH; Kao YH
BJU Int; 2012 Dec; 110(11 Pt C):E896-901. PubMed ID: 23035623
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
5. Low incidence of acute urinary retention in the general male population: the triumph project.
Verhamme KM; Dieleman JP; van Wijk MA; Bosch JL; Stricker BH; Sturkenboom MC
Eur Urol; 2005 Apr; 47(4):494-8. PubMed ID: 15774248
[TBL] [Abstract][Full Text] [Related]
6. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
[TBL] [Abstract][Full Text] [Related]
7. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
8. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F; Adjali K; Gomez Guerra L; Hong SJ; El Khalid S; Ratana-Olarn K;
BJU Int; 2012 Jan; 109(1):88-95. PubMed ID: 22117624
[TBL] [Abstract][Full Text] [Related]
9. The natural history of benign prostatic hyperplasia.
Fitzpatrick JM
BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
[TBL] [Abstract][Full Text] [Related]
10. Inhaled anticholinergic drugs and risk of acute urinary retention.
Afonso AS; Verhamme KM; Stricker BH; Sturkenboom MC; Brusselle GG
BJU Int; 2011 Apr; 107(8):1265-72. PubMed ID: 20880196
[TBL] [Abstract][Full Text] [Related]
11. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia.
Lucas MG; Stephenson TP; Nargund V
BJU Int; 2005 Feb; 95(3):354-7. PubMed ID: 15679793
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of recurrent acute urinary retention in BPH patients in the United States: Retrospective analysis of US-based insurance claims database.
Lee S; Yoo KH; Kim TS; Cho HJ; Kim W; Oh JK; Li S; Kim SY; Wei W; Huang J; van Uem S; Del Giudice F; Lindars DP; Sathe AR; Chung BI
Prostate; 2023 May; 83(7):722-728. PubMed ID: 36891865
[TBL] [Abstract][Full Text] [Related]
13. The role of bladder diverticula in the prevalence of acute urinary retention in patients with BPH who are candidates to surgery.
Iscaife A; Dos Anjos G; Barbosa C; Nahas WC; Srougi M; Antunes AA
Int Braz J Urol; 2018; 44(4):765-770. PubMed ID: 29617085
[TBL] [Abstract][Full Text] [Related]
14. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.
Boyle P; Roehrborn C; Harkaway R; Logie J; de la Rosette J; Emberton M
Eur Urol; 2004 May; 45(5):620-6; discussion 626-7. PubMed ID: 15082205
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia.
Prieto L; Romero J; López C; Ortiz M; Pacheco JJ
Urol Int; 2008; 81(1):66-71. PubMed ID: 18645274
[TBL] [Abstract][Full Text] [Related]
16. The Reten-World survey of the management of acute urinary retention: preliminary results.
Emberton M; Fitzpatrick JM
BJU Int; 2008 Mar; 101 Suppl 3():27-32. PubMed ID: 18307683
[TBL] [Abstract][Full Text] [Related]
17. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group.
Roehrborn CG; Bruskewitz R; Nickel GC; Glickman S; Cox C; Anderson R; Kandzari S; Herlihy R; Kornitzer G; Brown BT; Holtgrewe HL; Taylor A; Wang D; Waldstreicher J
Eur Urol; 2000 May; 37(5):528-36. PubMed ID: 10765090
[TBL] [Abstract][Full Text] [Related]
18. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction.
Alan McNeill S
Eur Urol; 2004 Mar; 45(3):325-32. PubMed ID: 15036678
[TBL] [Abstract][Full Text] [Related]
19. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
McNeill SA; Hargreave TB; Roehrborn CG;
Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
[TBL] [Abstract][Full Text] [Related]
20. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
